Cancer-Related Triplets of MRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2017 Mar 11

PMID 28280730

Citations 20

Authors

Chenglin Liu

Yu-Hang Zhang

Qinfang Deng

Yixue Li

Tao Huang

Songwen Zhou

Yu-Dong Cai

Affiliations

Soon will be listed here.

Abstract

The regulation of transcriptome expression level is a complex process involving multiple-level interactions among molecules such as protein coding RNA (mRNA), long noncoding RNA (lncRNA), and microRNA (miRNA), which are essential for the transcriptome stability and maintenance and regulation of body homeostasis. The availability of multilevel expression data enables a comprehensive view of the regulatory network. In this study, we analyzed the coding and noncoding gene expression profiles of 301 patients with uterine corpus endometrial carcinoma (UCEC). A new method was proposed to construct a genome-wide integrative network based on variance inflation factor (VIF) regression method. The cross-regulation relations of mRNA, lncRNA, and miRNA were then selected based on clique-searching algorithm from the network, when any two molecules of the three were shown as interacting according to the integrative network. Such relation, which we call the mRNA-lncRNA-miRNA triplet, demonstrated the complexity in transcriptome regulation process. Finally, six UCEC-related triplets were selected in which the mRNA participates in endometrial carcinoma pathway, such as CDH1 and TP53. The multi-type RNAs are proved to be cross-regulated as to each of the six triplets according to literature. All the triplets demonstrated the association with the initiation and progression of UCEC. Our method provides a comprehensive strategy for the investigation of transcriptome regulation mechanism.

Citing Articles

Deciphering DNA repair gene mutational landscape in uterine corpus endometrial carcinoma patients using next generation sequencing.

Lou J, Chu X, Yang X, Jamil M, Zhu H Am J Cancer Res. 2024; 14(1):210-226.

PMID: 38323278 PMC: 10839304.

TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification.

Miao L, Chen B, Jing L, Zeng T, Chen Y Recent Pat Anticancer Drug Discov. 2024; 20(1):71-88.

PMID: 38305309 DOI: 10.2174/0115748928267447231107101539.

CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.

Wang G, Fu J, Liu M, Zheng Q PLoS One. 2024; 19(1):e0277872.

PMID: 38232115 PMC: 10793908. DOI: 10.1371/journal.pone.0277872.

The Role of miRNAs in the Development, Proliferation, and Progression of Endometrial Cancer.

Bogaczyk A, Zawlik I, Zuzak T, Kluz M, Potocka N, Kluz T Int J Mol Sci. 2023; 24(14).

PMID: 37511248 PMC: 10380838. DOI: 10.3390/ijms241411489.

Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.

Zhang C, Wang R, Li M, Yang Q Oncol Rep. 2023; 49(5).

PMID: 37052291 PMC: 10152453. DOI: 10.3892/or.2023.8544.

References

Chmelarova M, Kos S, Dvorakova E, Spacek J, Laco J, Ruszova E . Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium. Clin Chem Lab Med. 2014; 52(8):1229-34. DOI: 10.1515/cclm-2013-0162. View

Yoon J, Abdelmohsen K, Gorospe M . Functional interactions among microRNAs and long noncoding RNAs. Semin Cell Dev Biol. 2014; 34:9-14. PMC: 4163095. DOI: 10.1016/j.semcdb.2014.05.015. View

Dong R, Qiu H, Du G, Wang Y, Yu J, Mao C . Restoration of microRNA‑218 increases cellular chemosensitivity to cervical cancer by inhibiting cell‑cycle progression. Mol Med Rep. 2014; 10(6):3289-95. DOI: 10.3892/mmr.2014.2622. View

Sanchez Y, Segura V, Marin-Bejar O, Athie A, Marchese F, Gonzalez J . Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat Commun. 2014; 5:5812. PMC: 4284803. DOI: 10.1038/ncomms6812. View

Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L . Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol. 2013; 24(12):3082-8. PMC: 3841017. DOI: 10.1093/annonc/mdt380. View

Li J, Chen Y, Zhao J, Kong F, Zhang Y . miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett. 2011; 304(1):52-9. DOI: 10.1016/j.canlet.2011.02.003. View

Mungamuri S, Wang S, Manfredi J, Gu W, Aaronson S . Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters. Oncogene. 2014; 34(19):2461-70. PMC: 4295002. DOI: 10.1038/onc.2014.198. View

. 2012 International Cancer Education Conference Proceedings. J Cancer Educ. 2014; 30 Suppl 1:1-96. DOI: 10.1007/s13187-014-0759-y. View

Peng B, Li D, Qin M, Luo D, Zhang X, Zhao H . MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus. Tumour Biol. 2013; 35(4):3831-7. DOI: 10.1007/s13277-013-1507-3. View

10.

Saito T, Mimori K . [Cancer stemness and circulating tumor cells]. Nihon Rinsho. 2015; 73(5):806-10. View

11.

Silies M, Klambt C . APC/C(Fzr/Cdh1)-dependent regulation of cell adhesion controls glial migration in the Drosophila PNS. Nat Neurosci. 2010; 13(11):1357-64. DOI: 10.1038/nn.2656. View

12.

Zhao J, Zhang S, Wu L, Zhang X . Efficient methods for identifying mutated driver pathways in cancer. Bioinformatics. 2012; 28(22):2940-7. DOI: 10.1093/bioinformatics/bts564. View

13.

Hsiao S, Chen M, Chen C, Chien M, Hua K, Hsiao M . The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer. Ann Surg Oncol. 2015; 22 Suppl 3:S1556-65. DOI: 10.1245/s10434-015-4379-5. View

14.

Neppe C, Land R, Obermair A . Wrigley forceps to deliver a bulky uterus following a total laparoscopic hysterectomy for endometrial cancer. Aust N Z J Obstet Gynaecol. 2005; 45(5):444-5. DOI: 10.1111/j.1479-828X.2005.00460.x. View

15.

Qian Z, Sano T, Yoshimoto K, Asa S, Yamada S, Mizusawa N . Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol. 2007; 20(12):1269-77. DOI: 10.1038/modpathol.3800965. View

16.

Yeang C, McCormick F, Levine A . Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008; 22(8):2605-22. DOI: 10.1096/fj.08-108985. View

17.

Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S . Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood. 2013; 121(18):3650-7. DOI: 10.1182/blood-2012-10-458695. View

18.

Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X . Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers. 2013; 29(1):e21-9. DOI: 10.5301/jbm.5000047. View

19.

El Behery M, Huda M, Kamal E, Shehatta A . Diagnostic accuracy of uterine fluid lactate dehydrogenase isoenzyme activity profile and vaginal ultrasound in detecting endometrial cancer in women with postmenopausal bleeding. Arch Gynecol Obstet. 2009; 281(4):717-21. DOI: 10.1007/s00404-009-1231-9. View

20.

Lee J, Kim H, Lee E, Lee H, Kim J, Kim M . One case of endometrial cancer occurrence: Over 10 years after colon cancer in Lynch family. Obstet Gynecol Sci. 2014; 56(6):408-11. PMC: 3859014. DOI: 10.5468/ogs.2013.56.6.408. View